TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
How It Works
Start Here
Spark Generator
Stock Deep Dives
AI Analyst
Agentic Chat
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Spark Charts
AI Technical Analysis
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
Members AreaMembers Area
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·May 4, 2026

Twist Bioscience Corporation (TWST) drops on earnings misses

Twist Bioscience Corporation (TWST) drops 5.5% after reporting earnings misses, as investors react to weaker-than-expected results and reassess the stock's near-term outlook.

Earnings FlashTWSTHealthcareMedical - Diagnostics & Research
By TickerSpark·May 4, 2026·2 min read
Twist Bioscience Corporation (TWST) drops on earnings misses
▌Key Takeaway
Twist Bioscience Corporation (TWST) fell 5.50% after reporting a wider-than-expected quarterly loss, with EPS of -0.71 versus -0.54 expected. Revenue narrowly beat estimates at $0.11 billion, but the market focused on the second straight earnings miss and the lack of clear margin improvement.

Twist Bioscience Corporation (TWST) drops after earnings miss

Twist Bioscience Corporation (TWST) missed on EPS and narrowly beat on revenue, posting EPS of -0.71 versus -0.54 expected and revenue of $0.11B versus $0.11B expected, while the stock fell 5.50% in regular-session trading to $57.08.

Key Numbers

  • EPS: -0.71 vs -0.54 estimate, a miss.

§ Product

  • How It Works
  • Spark Generator
  • AI Analyst
  • Plans

§ Research

  • Main Feed
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $0.11B vs $0.11B estimate, a beat.
  • Stock reaction: TWST closed at $57.08, down 5.50% in regular-session trading from the prior close of $60.40.
  • Intraday range: shares traded between $56.01 and $59.99.
  • Recent earnings trend: this follows a smaller EPS miss in the prior quarter, when TWST reported -0.50 versus -0.48 estimated on 2026-02-02.

    • Profit pressure outweighed the revenue beat

    The market focused on profitability. Twist Bioscience beat on revenue, but the EPS miss was wider and landed after a prior-quarter miss as well. For a $3.5B growth company, that is usually enough to pressure the stock, especially when the top-line beat is only slight.

    The recent pattern is mixed. Twist beat EPS in two of the three quarters before this report, but it has now missed in back-to-back quarters. That shifts attention back to cost control and operating leverage. In plain English, investors want revenue growth to turn into smaller losses, not bigger disappointment.

    The 5.50% drop in regular-session trading shows the market treated this as a margin story, not a sales story. When a company clears the revenue bar but still gets sold, investors are usually telling management that execution below the gross line matters more right now.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    Twist Bioscience delivered enough revenue to edge past estimates, but the deeper EPS miss and a second straight quarterly shortfall sent TWST lower and kept the focus on profitability.

    Read the full TWST research report
    ▌Common Questions

    Frequently asked questions

    +Why did Twist Bioscience stock drop after earnings?
    Twist Bioscience Corporation (TWST) fell because its EPS miss was larger than expected, even though revenue slightly beat estimates. Investors focused on profitability, and the stock closed down 5.50% at $57.08.
    +Did Twist Bioscience beat revenue and miss earnings in the latest quarter?
    Yes. Twist Bioscience reported revenue of $0.11 billion versus $0.11 billion expected, but EPS came in at -0.71 compared with the -0.54 estimate. The market treated the earnings miss as the more important result.
    +How much did TWST stock move after the earnings report?
    TWST closed at $57.08, down 5.50% in regular-session trading from the prior close of $60.40. Shares traded between $56.01 and $59.99 during the session.
    +What does Twist Bioscience's earnings miss mean for investors?
    The report suggests investors are still waiting for revenue growth to translate into better operating leverage and smaller losses. With back-to-back EPS misses, the market is likely to stay focused on cost control and margin improvement.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on TWST?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the TWST report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full TWST research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the TWST report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on TWST

    More to read

    All articles
    Twist Bioscience Corporation (TWST) drops after deep earnings miss
    TWST

    Twist Bioscience Corporation (TWST) drops after deep earnings miss

    Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.

    May 5·10 min
    Twist Bioscience (TWST): Margin Gains, But Valuation Is Rich
    TWST

    Twist Bioscience (TWST): Margin Gains, But Valuation Is Rich

    Twist Bioscience is scaling revenue, expanding gross margin, and gaining traction in AI-enabled discovery, but the stock already prices in much of the progress. Our view is Hold as the company works toward profitability.

    May 4·22 min
    ATII Holdings SPAC Merger: The Bull and Bear Case

    ATII Holdings SPAC Merger: The Bull and Bear Case

    ATII Holdings is going public through a merger with Archimedes Tech SPAC Partners II Co., with the combined company expected to trade on Nasdaq under NANO. The bull case is a domestic semiconductor-and-battery platform with a $100 million PIPE; the bear case is classic de-SPAC dilution and redemption risk.

    Jul 5·6 min